Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50861 |
Name | colorectal adenocarcinoma |
Definition | A colorectal carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colorectal carcinoma colorectal adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | DEL-22379 | colorectal adenocarcinoma | sensitive | detail... |
FGFR2 amp | RO4987655 | colorectal adenocarcinoma | decreased response | detail... |
FGFR2 amp | RO5126766 | colorectal adenocarcinoma | predicted - sensitive | detail... |
FGFR2 amp | Selumetinib | colorectal adenocarcinoma | no benefit | detail... |
CTNNB1 S45F | NTRC 0066-0 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | NTRC 0066-0 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | Mps-BAY2b | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | Mps-BAY2b | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | NMS-P715 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | NMS-P715 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45del | BAY1161909 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | BAY1161909 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | BAY1217389 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | BAY1217389 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | Mps1-IN-1 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | Mps1-IN-1 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | MPI-0479605 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | MPI-0479605 | colorectal adenocarcinoma | predicted - sensitive | detail... |
ARID1A inact mut | unspecified immune checkpoint inhibitor | colorectal adenocarcinoma | unknown | detail... |
BRAF V600E | ASTX029 | colorectal adenocarcinoma | sensitive | detail... |
ATM I1294Nfs*8 ATM E2977Rfs*2 | Irinotecan + Olaparib | colorectal adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | RO5126766 | colorectal adenocarcinoma | sensitive | detail... |
FGFR2 amp | Lirafugratinib | colorectal adenocarcinoma | sensitive | detail... |
PIK3CA E545G | Mirdametinib + Palbociclib | colorectal adenocarcinoma | sensitive | detail... |
PIK3CA E545G | Gedatolisib + Palbociclib | colorectal adenocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00113763 | Phase III | Panitumumab | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | Completed | 0 | |
NCT00408772 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin | Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery | Withdrawn | USA | 0 |
NCT00842257 | Phase II | Panitumumab | Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer | Completed | USA | 0 |
NCT01061515 | Phase I | Capecitabine Bevacizumab Oxaliplatin | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT01079780 | Phase II | Cetuximab + Irinotecan + Ramucirumab Cetuximab + Irinotecan | Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | Completed | USA | 0 |
NCT01420874 | Phase I | EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | Completed | USA | 0 |
NCT01442935 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | Completed | FRA | 0 |
NCT01471353 | Phase II | Capecitabine + Sorafenib | Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01571284 | Phase III | Aflibercept + Fluorouracil + Irinotecan + Leucovorin | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | Completed | USA | TUR | SWE | NOR | NLD | LBN | ITA | ISR | IRL | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | 5 |
NCT01622543 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Pelareorep | Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer | Completed | CAN | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01652196 | Phase II | Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | Completed | USA | 0 |
NCT01652482 | Phase II | Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin | A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | ROU | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT01802320 | Phase II | MK2206 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01814501 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | Completed | USA | 0 |
NCT01851369 | Phase Ib/II | Temozolomide + TRC102 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01949194 | Phase II | Regorafenib | Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers | Unknown status | CAN | 0 |
NCT02023333 | Phase II | Regorafenib | Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02116894 | Phase I | Ascrinvacumab + Regorafenib | Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer | Completed | USA | 0 |
NCT02149108 | Phase III | Nintedanib | Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer | Completed | USA | TUR | SWE | POL | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | ARG | 7 |
NCT02235324 | Phase II | Aflibercept + Fluorouracil + Leucovorin Aflibercept | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | Withdrawn | USA | 0 |
NCT02248805 | Phase I | MGD007 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | Completed | USA | 0 |
NCT02292758 | Phase II | Bevacizumab + Cetuximab + Irinotecan Cetuximab + Irinotecan | Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02368886 | Phase II | Clobetasol + Regorafenib | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02375672 | Phase II | Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02413853 | Phase II | Bevacizumab PRI-724 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT02466009 | Phase II | Regorafenib | Regorafenib in Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02574663 | Phase I | Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02602327 | Phase I | Trifluridine-tipiracil hydrochloride | Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases | Completed | USA | 0 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02651415 | Phase II | Perindopril + Regorafenib | Phase II Study of Perindopril and Regorafenib in mCRC | Completed | CAN | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT02780700 | Phase II | Capecitabine + Nintedanib Nintedanib | Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] | Terminated | USA | 0 |
NCT02835833 | Phase I | Bevacizumab + Nintedanib | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | USA | 0 |
NCT02860546 | Phase II | Nivolumab + Trifluridine-tipiracil hydrochloride | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | Completed | USA | 0 |
NCT02876224 | Phase I | Atezolizumab + Bevacizumab + Cobimetinib | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | Completed | USA | ESP | 0 |
NCT02885753 | Phase III | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR) | Recruiting | FRA | BEL | 0 |
NCT02908451 | Phase I | AbGn-107 | A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer | Terminated | USA | 1 |
NCT03007407 | Phase II | Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | Completed | USA | 0 |
NCT03069950 | Phase II | Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver | Withdrawn | USA | 0 |
NCT03081494 | Phase I | Regorafenib + Spartalizumab | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Completed | NLD | ITA | ISR | ESP | CAN | AUS | 2 |
NCT03087071 | Phase II | Panitumumab Panitumumab + Trametinib | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
NCT03104439 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03117972 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (CLavSyn) | Terminated | FRA | 0 |
NCT03186326 | Phase II | Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Avelumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) | Completed | FRA | 0 |
NCT03192345 | Phase I | Cemiplimab + SAR439459 SAR439459 | A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | EST | ESP | DEU | CAN | BEL | AUS | 2 |
NCT03258398 | Phase II | Avelumab + Tomivosertib Tomivosertib | A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer | Completed | USA | 0 |
NCT03277209 | Phase I | Plerixafor | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | Terminated | USA | GBR | 0 |
NCT03300609 | Phase III | Capecitabine Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Fluorouracil + Leucovorin + Panitumumab | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | Terminated | USA | 0 |
NCT03332498 | Phase Ib/II | Ibrutinib + Pembrolizumab | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | Completed | USA | 0 |
NCT03337087 | Phase Ib/II | Fluorouracil + Leucovorin + Liposomal irinotecan + Rucaparib | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | Active, not recruiting | USA | 0 |
NCT03366155 | Phase II | Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | Active, not recruiting | USA | 0 |
NCT03368963 | Phase Ib/II | Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Active, not recruiting | USA | 0 |
NCT03373188 | Phase I | Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | Completed | USA | 0 |
NCT03376659 | Phase Ib/II | Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitabine + CV301 + Durvalumab | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT03377361 | Phase Ib/II | Regorafenib Ipilimumab + Nivolumab + Trametinib Nivolumab + Trametinib | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9) | Completed | USA | ITA | ESP | DEU | CZE | CAN | BEL | AUS | ARG | 1 |
NCT03384940 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Completed | USA | ITA | GBR | ESP | 1 |
NCT03396926 | Phase II | Bevacizumab + Capecitabine + Pembrolizumab | Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03436563 | Phase Ib/II | Bintrafusp alfa | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | Completed | USA | 0 |
NCT03442569 | Phase II | Ipilimumab + Nivolumab + Panitumumab | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | Completed | USA | 0 |
NCT03475004 | Phase II | Bevacizumab + Binimetinib + Pembrolizumab | Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | Completed | USA | 0 |
NCT03539822 | Phase I | Cabozantinib + Durvalumab | Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) | Recruiting | USA | 0 |
NCT03542877 | Phase II | Cabozantinib | Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03576963 | Phase Ib/II | Guadecitabine + Nivolumab | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT03597581 | Phase I | RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202 | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | Completed | USA | 0 |
NCT03608046 | Phase II | Avelumab + Cetuximab + Irinotecan | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI) | Unknown status | BEL | 0 |
NCT03610490 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT03626922 | Phase I | Folic Acid Cyanocobalamin Oxaliplatin + Pembrolizumab + Pemetrexed Disodium Dexamethasone Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | Unknown status | USA | 0 |
NCT03642067 | Phase II | Nivolumab + Relatlimab | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | Completed | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Completed | USA | AUS | 4 |
NCT03712943 | Phase I | Nivolumab + Regorafenib | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer | Completed | USA | 0 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | ITA | GBR | FRA | ESP | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03750786 | Phase III | Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT) | Completed | USA | SWE | GRC | FRA | ESP | DEU | CAN | AUT | AUS | 1 |
NCT03800602 | Phase II | Metformin + Nivolumab | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | Completed | USA | 0 |
NCT03828227 | Phase III | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine | Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters (COLAGE) | Active, not recruiting | FRA | 0 |
NCT03874026 | Phase II | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA) | Recruiting | ITA | 0 |
NCT04014530 | Phase Ib/II | Pembrolizumab + PTC124 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study (ATAPEMBRO) | Unknown status | NLD | 0 |
NCT04054752 | Phase I | NT-I7 | Vaccine Response With NT-I7 | Withdrawn | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04094688 | Phase III | Bevacizumab + Cholecalciferol + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Cholecalciferol + Fluorouracil + Irinotecan + Leucovorin | Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer (SOLARIS) | Active, not recruiting | USA | 1 |
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Active, not recruiting | USA | 0 |
NCT04117945 | Phase II | Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04119830 | Phase II | Pembrolizumab + Rintatolimod | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | Withdrawn | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |
NCT04166435 | Phase II | Olaparib + Temozolomide | TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer | Completed | USA | 0 |
NCT04171141 | Phase I | PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Terminated | USA | AUS | 1 |
NCT04188145 | Phase III | Capecitabine Fluorouracil + Leucovorin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine | A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (BEVAMAINT) | Recruiting | FRA | 0 |
NCT04214418 | Phase Ib/II | Atezolizumab + Cobimetinib + Hydroxychloroquine | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) | Terminated | USA | 0 |
NCT04262687 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin + Pembrolizumab | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (POCHI) | Recruiting | FRA | 0 |
NCT04310176 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil Bevacizumab + Fluorouracil + Valproic acid Bevacizumab + Capecitabine + Valproic acid Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION) | Unknown status | ITA | 0 |
NCT04322539 | Phase III | Fruquintinib | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer (FRESCO-2) | Completed | USA | POL | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | BEL | AUT | AUS | 1 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04444622 | Phase II | Allostim | Immunotherapy for Third Line Metastatic Colorectal Cancer (STIMVAX) | Active, not recruiting | USA | 0 |
NCT04456699 | Phase III | Bevacizumab + Olaparib Bevacizumab + Fluorouracil Olaparib | Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU) | Completed | USA | TUR | LVA | LTU | HUN | FRA | ESP | DEU | CAN | BEL | AUS | 7 |
NCT04457284 | Phase II | Cisplatin + Nivolumab + Temozolomide | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04474470 | Phase Ib/II | Cetuximab + NT219 NT219 | A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | Completed | USA | ISR | 0 |
NCT04491955 | Phase II | Bintrafusp alfa + CV301 + NHS-IL12 + Nogapendekin alfa inbakicept Bintrafusp alfa + CV301 + Nogapendekin alfa inbakicept | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers | Completed | USA | 0 |
NCT04513951 | Phase II | Avelumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC) | Completed | ITA | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 Enzalutamide + PF-07220060 PF-07220060 Midazolam + PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | SVK | GBR | CZE | ARG | 3 |
NCT04575922 | Phase II | Ipilimumab + Nivolumab | Nivolumab+Ipilimumab+RT in MSS mCRC | Unknown status | USA | 0 |
NCT04660812 | Phase Ib/II | AB680 + Etrumadenant + Zimberelimab Regorafenib Bevacizumab + Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (ARC-9) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | 1 |
NCT04689347 | Phase I | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Temozolomide | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | Unknown status | ITA | 0 |
NCT04729322 | Phase I | Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | Active, not recruiting | USA | 0 |
NCT04730544 | Phase II | Ipilimumab + Nivolumab | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) | Active, not recruiting | FRA | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Completed | USA | ISR | ESP | 0 |
NCT04744831 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02) | Completed | USA | ITA | GBR | FRA | ESP | BEL | AUS | 3 |
NCT04776148 | Phase III | Regorafenib Trifluridine-tipiracil hydrochloride Lenvatinib + Pembrolizumab | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | Completed | USA | TUR | ISR | GBR | ESP | DNK | DEU | CAN | AUS | ARG | 5 |
NCT04776655 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) | Recruiting | ITA | 0 |
NCT04853043 | Phase II | Cetuximab | Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT04868773 | Phase I | Cabozantinib + Trifluridine-tipiracil hydrochloride | Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | Active, not recruiting | USA | 0 |
NCT04873895 | Phase I | Axitinib + Hydroxychloroquine | TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC) (TACE-Ax-HCQ) | Terminated | USA | 0 |
NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | HUN | GRC | GBR | FRA | EST | ESP | DNK | DEU | CAN | BEL | 5 |
NCT04952753 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) | Terminated | USA | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUS | 5 |
NCT04963283 | Phase II | Cabozantinib + Nivolumab | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05064059 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride MK-4280A | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | Completed | USA | TUR | NOR | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 9 |
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | TUR | POL | NZL | LTU | ITA | ISR | ESP | DNK | CHE | CAN | AUS | 7 |
NCT05075564 | Phase I | ES002023 | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT05087992 | Phase I | Bevacizumab + BI 905711 + Fluorouracil + Irinotecan + Leucovorin BI 905711 + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | Completed | USA | FRA | BEL | 2 |
NCT05121038 | Phase Ib/II | CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) | Active, not recruiting | USA | 0 |
NCT05130060 | Phase I | PolyPEPI1018 + Trifluridine-tipiracil hydrochloride | A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT05198934 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride Panitumumab + Sotorasib | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak300) | Active, not recruiting | USA | ITA | GRC | GBR | FRA | ESP | DEU | AUS | 4 |
NCT05200442 | Phase Ib/II | Cetuximab + RO5126766 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Suspended | USA | 0 |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Terminated | USA | 0 |
NCT05223673 | Phase III | Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) | Terminated | USA | HUN | FIN | DNK | BEL | 1 |
NCT05253651 | Phase III | Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) | Recruiting | USA | SVK | POL | NOR | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT05286814 | Phase II | Fluorouracil + Leucovorin + NHS-IL12 + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NHS-IL12 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT05291156 | Phase II | Cetuximab Avelumab + Cetuximab | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | Recruiting | ITA | 0 |
NCT05310643 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC (NIPIRESCUE) | Recruiting | FRA | 0 |
NCT05312398 | Phase II | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen | Active, not recruiting | ITA | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Active, not recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05328908 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride Nivolumab and relatlimab-rmbw | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) | Active, not recruiting | USA | SWE | POL | NLD | ITA | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | ARG | 7 |
NCT05330429 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05382442 | Phase II | Ivonescimab Fluorouracil + Ivonescimab + Leucovorin + Oxaliplatin AK117 + Fluorouracil + Irinotecan + Ivonescimab + Leucovorin + Oxaliplatin AK117 + Fluorouracil + Ivonescimab + Leucovorin AK117 + Capecitabine + Ivonescimab + Oxaliplatin AK117 + Capecitabine + Ivonescimab Fluorouracil + Ivonescimab + Leucovorin AK117 + Ivonescimab Capecitabine + Ivonescimab + Oxaliplatin Fluorouracil + Irinotecan + Ivonescimab + Leucovorin + Oxaliplatin | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Recruiting | USA | 1 |
NCT05382741 | Phase II | Durvalumab + Regorafenib | Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA) | Unknown status | ITA | 0 |
NCT05429762 | Phase I | SAR408701 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) | Terminated | USA | TUR | FRA | ESP | BEL | 0 |
NCT05482516 | Phase III | Atezolizumab + Bevacizumab | Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) | Recruiting | USA | 0 |
NCT05504252 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Nivolumab | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (METIMMOX-2) | Recruiting | NOR | 0 |
NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Terminated | USA | CAN | 0 |
NCT05589597 | Phase Ib/II | EO4010 + Nivolumab EO4010 | EO4010 in Previously Treated Metastatic Colorectal Carcinoma (AUDREY) | Active, not recruiting | USA | FRA | ESP | 0 |
NCT05608044 | Phase II | Balstilimab + Botensilimab Botensilimab | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Active, not recruiting | USA | ITA | FRA | ESP | BRA | BEL | 2 |
NCT05609370 | Phase Ib/II | Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab Bevacizumab + Fluorouracil + LBL-007 Bevacizumab + Fluorouracil Bevacizumab + Capecitabine + LBL-007 + Tislelizumab Bevacizumab + Capecitabine + LBL-007 | A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | Active, not recruiting | USA | AUS | 2 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Withdrawn | USA | 0 |
NCT05631327 | Phase I | JZP341 | JZP341 Phase 1 Dose-Finding Study in Adult Participants With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Terminated | USA | 1 |
NCT05733611 | Phase II | Atezolizumab + Bevacizumab + RP2 Atezolizumab + Bevacizumab + RP3 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Active, not recruiting | 0 | |
NCT05743036 | Phase Ib/II | Azenosertib + Cetuximab + Encorafenib | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | Active, not recruiting | USA | POL | ITA | HUN | ESP | DEU | AUS | 0 |
NCT05784688 | Phase Ib/II | Pembrolizumab + TU2218 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05845450 | Phase II | Durvalumab Trastuzumab deruxtecan Panitumumab + Sotorasib Vorbipiprant Balstilimab + Botensilimab Nivolumab + Vorbipiprant Panitumumab Botensilimab | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | Recruiting | ITA | 0 |
NCT05848843 | Phase I | Adagrasib + Durvalumab | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | USA | 0 |
NCT05854498 | Phase II | Bevacizumab + Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05877599 | Phase I | NT-175 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Recruiting | USA | 0 |
NCT05909423 | Phase II | Influenza vaccine + Pembrolizumab | Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer (FLU-IMMUNE) | Not yet recruiting | DNK | 0 |
NCT05983367 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | Active, not recruiting | FRA | ESP | BEL | 0 |
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |
NCT06043713 | Phase I | Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Active, not recruiting | USA | 0 |
NCT06102902 | Phase I | Cetuximab + Encorafenib + ZEN-3694 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | Recruiting | USA | 0 |
NCT06178614 | Phase I | JNJ-87890387 | A Study of JNJ-87890387 for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT06207656 | Phase II | Binimetinib + Cetuximab + Encorafenib | Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer (CEBBRA) | Recruiting | ESP | 0 |
NCT06218914 | Phase I | NT-112 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Active, not recruiting | USA | 0 |
NCT06252649 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab + Sotorasib | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naive Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | Recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CHE | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
NCT06300463 | Phase II | Balstilimab + Botensilimab + GS-1423 Balstilimab + Botensilimab | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Recruiting | USA | 0 |
NCT06314997 | Phase II | Panitumumab | Dynamic Changes in Circulating Tumour Cells Protein Expression (Liquid-DRER2) | Recruiting | ITA | 0 |
NCT06445062 | Phase Ib/II | Cetuximab + Daraxonrasib + Fluorouracil + Leucovorin + Oxaliplatin Daraxonrasib + Gemcitabine + Nab-paclitaxel Bevacizumab + Daraxonrasib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Daraxonrasib Bevacizumab + Daraxonrasib + Fluorouracil + Leucovorin + Oxaliplatin | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | USA | 0 |
NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06529523 | Phase II | Tislelizumab | Tislelizumab in People With Colorectal Cancer | Recruiting | USA | 1 |
NCT06557278 | Phase II | Allostim + Avelumab | Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer (COMUNITY) | Not yet recruiting | USA | 0 |
NCT06578559 | Phase II | Cetuximab + Encorafenib | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET) | Recruiting | ITA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06640166 | Phase II | Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin | Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse) | Recruiting | ITA | 0 |
NCT06642844 | Phase III | Bevacizumab | Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment (PHARBEVACOL) | Not yet recruiting | 0 | |
NCT06662786 | Phase III | Oxaliplatin Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | 7 |
NCT06663319 | Phase I | JNJ-89402638 | A Study of JNJ-89402638 for Metastatic Colorectal Cancer | Recruiting | USA | ESP | 1 |
NCT06696768 | Phase I | Bevacizumab + CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT06714357 | Phase II | Irinotecan + Panitumumab + Valproic acid Irinotecan + Panitumumab | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/revert Resistance in Colorectal Cancer (VICTORIA) | Recruiting | ITA | 0 |
NCT06722183 | Phase II | Fluorouracil + Futibatinib + Leucovorin + Oxaliplatin + Tislelizumab | A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities (FUTURE) | Not yet recruiting | DEU | 0 |
NCT06730750 | Phase Ib/II | BMS-986490 Bevacizumab + BMS-986490 | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT06784947 | Phase II | Atezolizumab + Bevacizumab + Tiragolumab | A Phase II Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients with Microsatellite Stable, Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT06792695 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + MEDI5752 | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT06859762 | Phase I | YL217 | A First-in-Human Study of YL217 in Patients with Advanced Solid Tumors | Recruiting | USA | 1 |
NCT07011550 | Phase II | Bevacizumab + BMS-986340 + Nivolumab + Trifluridine-tipiracil hydrochloride | Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer | Not yet recruiting | USA | 0 |
NCT07016490 | Phase I | SSGJ-709 | A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors | Recruiting | AUS | 0 |